GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform

Generic drug user fees should only be considered in the context of changes to the Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA during a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.